08 January 2019 | News
CytoReason’s proprietary platform helps rebuild lost cellular information from gene expression data and associates genes to specific cells.
image credit- fieldofscience.com
CytoReason, a leader in machine learning for drug discovery and development, announced that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason’s cell-centered models of the immune system.
CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments.
CytoReason’s proprietary platform helps rebuild lost cellular information from gene expression data and associates genes to specific cells. This information is then integrated with additional omics and literature data to create a cell-based model of the trial-specific immune response. Integration with the CytoReason disease model empowers the study analytics and allows the model to learn and improve, leading to robust target discovery, drug response biomarkers and indication selection.
“The collaboration with Pfizer will further strengthen our models in our core therapeutic areas. This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline,” said David Harel, CytoReason’s CEO.